+ +

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

SDHC antibodies target the succinate dehydrogenase complex subunit C (SDHC), a key component of mitochondrial complex II (succinate-ubiquinone oxidoreductase) in the electron transport chain. Complex II catalyzes the oxidation of succinate to fumarate in the citric acid cycle while transferring electrons to ubiquinone. SDHC, along with SDHD, anchors the complex to the mitochondrial inner membrane, while SDHA and SDHB form the catalytic core.

Germline mutations in SDHC are linked to hereditary paraganglioma/pheochromocytoma (PGL/PCC), rare neuroendocrine tumors. SDHC dysfunction disrupts cellular energy metabolism and promotes pseudohypoxic signaling via HIF-1α stabilization, driving tumorigenesis. SDHC antibodies are vital tools for studying these mechanisms, enabling detection of protein expression loss in tumors with SDHx mutations. They are widely used in Western blot, immunohistochemistry (IHC), and immunofluorescence (IF) to assess SDHC localization and abundance in research models or clinical samples.

Additionally, SDHC antibodies aid in diagnosing SDH-deficient tumors, which exhibit distinct clinical behavior. Their specificity is critical, as cross-reactivity with other SDH subunits can confound results. Recent studies also explore SDHC's role beyond cancer, including mitochondrial disorders and metabolic adaptations in hypoxia. Commercial antibodies are typically validated using SDHC-knockout controls to ensure reliability. Overall, SDHC antibodies remain essential for advancing research into mitochondrial biology, cancer metabolism, and genetic tumor syndromes.